On 7 April, the FDA published several warning letters, including a batch to companies that the agency said are marketing GLP-1 products, dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) products, and triple agonist (GLP-1/GIP/glucagon) products without regulatory approval
When we pulled up a listing, the batch COA showed HPLC purity, LC-MS identity, sterility, endotoxin testing, and residual TFA upfront
Unsupervised Use: These peptides should only be administered under medical guidance to ensure dosing accuracy and safety
This peptide therapy is particularly beneficial when youre experiencing persistent muscle strains, tendon inflammation, ligament damage, or chronic joint pain that limits your performance
doi: 10.2174/1381612824666180614082950